Evidence map›Paper›PMID 30646858›Full record

ArticleBMC neurology2019

Futile reperfusion and predicted therapeutic benefits after successful endovascular treatment according to initial stroke severity.

Sang-Hwa Lee, Beom Joon Kim, Moon-Ku Han, Tai Hwan Park, Kyung Bok Lee, Byung-Chul Lee, Kyung-Ho Yu, Mi Sun Oh, Jae Kwan Cha, Dae-Hyun Kim and 23 more

2 registry-linked trialsOpen access · goldAbstract readMulticenter Study
In one paragraph

Article in BMC neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 30 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 2 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06429384 phase2completednot on this mapstarted 2023, after this paper: background citation

Y-3 Injection in the Treatment of Acute Ischemic Stroke Phase II Clinical Trial -- Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase II Clinical Trial

TypeinterventionalSponsorBeijing Tiantan HospitalRan2023 to 2023Enrolled240ConditionsAcute Ischemic StrokeArmsY-3 Injection/Y-3 blank injection
NCT06517173 phase3completednot on this mapstarted 2024, after this paper: background citation

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Y-3 in Chinese Subjects With Acute Ischemic Stroke

TypeinterventionalSponsorBeijing Tiantan HospitalRan2024 to 2025Enrolled998ConditionsAcute Ischemic StrokeArmsY-3 for injection, Placebo control group
3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 61 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. No-reflow after recanalization in ischemic stroke: From pathomechanisms to therapeutic strategies.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2024
    Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2023
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 20 institutions in 2 countries.

Sang-Hwa LeeDepartment of Neurology, Hallym University Chuncheon Sacred Heart Hospital, Chuncheon, Korea.
Beom Joon KimDepartment of Neurology, Seoul National University Bundang Hospital, Seongnam, Korea.
Moon-Ku HanDepartment of Neurology, Seoul National University Bundang Hospital, Seongnam, Korea.
Tai Hwan ParkDepartment of Neurology, Seoul Medical Center, Seoul, Korea.
Kyung Bok LeeDepartment of Neurology, Soonchunhyang University College of Medicine, Seoul, Korea.
Byung-Chul LeeDepartment of Neurology, Hallym University Sacred Heart Hospital, Anyang, Korea.
Kyung-Ho YuDepartment of Neurology, Hallym University Sacred Heart Hospital, Anyang, Korea.
Mi Sun OhDepartment of Neurology, Hallym University Sacred Heart Hospital, Anyang, Korea.
Jae Kwan ChaDepartment of Neurology, Dong-A University Hospital, Pusan, Korea.
Dae-Hyun KimDepartment of Neurology, Dong-A University Hospital, Pusan, Korea.
Hyun-Wook NahDepartment of Neurology, Dong-A University Hospital, Pusan, Korea.
Jun LeeDepartment of Neurology, Yeungnam University Medical Center, Daegu, Korea.
Soo Joo LeeDepartment of Neurology, Eulji University Hospital, Eulji University School of Medicine, Daejeon, Korea.
Jae Guk KimDepartment of Neurology, Eulji University Hospital, Eulji University School of Medicine, Daejeon, Korea.
Jong-Moo ParkDepartment of Neurology, Eulji General Hospital, Eulji University, Seoul, Korea.
Kyusik KangDepartment of Neurology, Eulji General Hospital, Eulji University, Seoul, Korea.
Yong-Jin ChoDepartment of Neurology, Ilsan Paik Hospital, Inje University, Goyang, Korea.
Keun-Sik HongDepartment of Neurology, Ilsan Paik Hospital, Inje University, Goyang, Korea.
Hong-Kyun ParkDepartment of Neurology, Ilsan Paik Hospital, Inje University, Goyang, Korea.
Jay Chol ChoiDepartment of Neurology, Jeju National University, Jeju, Korea.
Joon-Tae KimDepartment of Neurology, Chonnam National University Hospital, Gwangju, Korea.
Kangho ChoiDepartment of Neurology, Chonnam National University Hospital, Gwangju, Korea.
Dong-Eog KimDepartment of Neurology, Dongguk University Ilsan Hospital, Goyang, Korea.
Wi-Sun RyuDepartment of Neurology, Dongguk University Ilsan Hospital, Goyang, Korea.
Wook-Joo KimUlsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
Dong-Ick ShinDepartment of Neurology, Chungbuk National University College of Medicine, Cheongju, Korea.
Minju YeoDepartment of Neurology, Chungbuk National University College of Medicine, Cheongju, Korea.
Sung-Il SohnDepartment of Neurology, Keimyung University Dongsan Medical Center, Daegu, South Korea.
Jeong-Ho HongDepartment of Neurology, Keimyung University Dongsan Medical Center, Daegu, South Korea.
Juneyoung LeeDepartment of Biostatistics, Korea University College of Medicine, Seoul, Korea.
Ji Sung LeeClinical Research Center, Asan Medical Center, Seoul, Korea.
Pooja KhatriDepartment of Neurology, University of Cincinnati, Cincinnati, OH, USA.
Hee-Joon BaeDepartment of Neurology, Seoul National University Bundang Hospital, Seongnam, Korea. braindoc@snu.ac.kr.
Dong-A University Hospital · KRHallym University Sacred Heart Hospital · KRInje University Ilsan Paik Hospital · KRSeoul National University Bundang Hospital · KRAsan Medical Center · KRChonnam National University Hospital · KRChungbuk National University · KRDongguk University Ilsan Hospital · KRHallym University Chuncheon Sacred Heart Hospital · KRDaejeon Eulji Medical Center, Eulji University · KREulji Medical Center · KREulji University · KRJeju National University · KRKeimyung University · KRKeimyung University Dongsan Medical Center · KRSeoul Medical Center · KRSoonchunhyang University · KRUniversity of Cincinnati · USUniversity of Ulsan · KRYeungnam University Medical Center · KR

Funding

Research of Korea Centers for Disease Control and Prevention 2017ER620101#
6 · The paper itself

Abstract

backgroundFutile reperfusion (poor functional status despite successful reperfusion) was observed in up to 67% of patients enrolled in recent endovascular treatment (EVT) clinical trials. We investigated the impact of baseline stroke severity on both futile reperfusion and therapeutic benefit of successful EVT.

methodsUsing a prospective multicenter stroke registry, we identified consecutive ischemic stroke patients with anterior circulation large artery occlusion, who were reperfused successfully by EVT (Thrombolysis in Cerebral Infarction grade 2b-3). The rate of futile reperfusion was assessed across the initial National Institutes of Health Stroke Scale (NIHSS) scores. The frequency of poor outcomes (modified Rankin scale [mRS] 3-6) according to NIHSS scores was compared between patients revascularized successfully by EVT and those who did not receive EVT, after standardizing for age.

resultsAmong 21,591 patients with ischemic stroke, 972 (4.5%) received EVT within 12 h of onset, including 440 who met study eligibility criteria. Futile reperfusion was observed in 226 of the 440 study-eligible patients (51.4%) and was associated with stroke severity: 20.9% in NIHSS scores ≤5, 34.6% in 6-10, 58.9% in 11-20, and 63.8% in > 20 (p < 0.001). Nonetheless, the therapeutic benefit of EVT also increased with increasing stroke severity (p for interaction < 0.001): 0.1% in NIHSS ≤5, 18.6% in 6-10, 28.7% in 11-20, and 34.3% in > 20.

conclusionsEVT is more beneficial with increasing stroke severity, although futile reperfusion also increases with higher stroke severity.

Indexed as

AgedAged, 80 and overCerebral InfarctionEndovascular ProceduresFemaleHumansMaleMiddle AgedProspective StudiesRegistriesReperfusionStrokeThrombolytic TherapyTreatment OutcomeEndovascular treatmentFutile reperfusionStroke severityTherapeutic benefit

Identifiers

PMID30646858
PMCPMC6332890
OpenAlexW2915275239

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.